- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04488120
Occlutech Septal Occluder (Figulla Flex II) Study
A Randomized, Controlled,Multi-Centre Trial of the Efficacy and Safety of the Occlutech Septal Occluder(Figulla Flex II) Compared to the AGA Septal Occluder(Amplatzer ASO) for Transcatheter Closure of Secundum ASD in Patients
The objectives of the study are:
- To determine the efficacy of the Figulla Flex II device compared with that of the Amplatzer ASO device for transcatheter closure of secundum atrial septal defects
- To determine the safety of the Figulla Flex II device compared with that of the Amplatzer ASO device for transcatheter closure of secundum atrial septal defects
This is a randomized, controlled, multi-centre trial of the efficacy and safety of the Occlutech septal occluder (Figulla Flex II) compared to the AGA septal occluder (Amplatzer ASO) for transcatheter closure of secundum atrial septal defects in patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inclusion criteria A patient will be eligible for study participation if he/she meets the following criteria:
- Able to fluently speak and understand the language in which the study is being conducted
- Has ostium secundum atrial septal defect
- Has a defect hole with a diameter of < 38 mm
- Has a left-to-right shunt with a Qp/Qs ratio of . 1.5:1 or the presence of right ventricular volume overload determined by transthoracic echo (TTE) or clinical symptoms due to the atrial septal defect
- Has a distance of > 5 mm from the margins of the defect(s) to the coronary sinus, arterioventricular (AV) valves and right upper pulmonary vein as measured by echocardiography
- Agrees to participate in the study and comply with the follow-up schedule
- Is willing to freely give (or Legally Authorized Representative is willing to freely give) Informed Consent prior to treatment
- Willing to return for the post-treatment evaluation. Exclusion criteria
A patient will be excluded from the study if he/she meets the following criteria:
- Has multiple defects which can�ft adequately be covered by the device
Has associated congenital cardiac anomalies which require cardiac surgery
a. Has a known sensitivity to contrast media that cannot be controlled adequately with pre-medication.
- Patient is currently participating in another clinical device or drug trial that has not completed its primary endpoint or that will clinically confound the current study endpoints or does not permit subjects to participate in other studies. Typically, subjects that are involved in the long-term surveillance phase of a clinical study are eligible.
- Has ostium primum atrial septal defects
- Has sinus venosus atrial septal defects
- Has partial anomolous pulmonary venous drainage
- Has pulmonary vascular resistance above 7 Woods units or a right-toleft shunt at the atrial level with a peripheral arterial saturation less than 94%
- Has a recent myocardial infarction, unstable angina and decompensated congestive heart failure (CHF)
- Has right and/or left ventricular decompensation with ejection fraction of < 30%
- Has an active bacterial and/or viral infection
- Has any type of serious infection < 1 month prior to the procedure
- Has malignancy where life expectancy is < 2 years
- Has demonstrated intracardiac thrombi on echocardiography
- Weighs < 8 kg
- Has gastritis, gastric ulcer, duodenal ulcer, etc. and other contraindications to aspirin therapy unless other anti-platelet agents can be administered for 6 months
- Has an unstable condition or otherwise thought to be unreliable or incapable of complying with the requirements of the clinical investigational plan (CIP).
- Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient will be eligible for study participation if he/she meets the following criteria:
- Able to fluently speak and understand the language in which the study is being conducted
- Has ostium secundum atrial septal defect
- Has a defect hole with a diameter of < 38 mm
- Has a left-to-right shunt with a Qp/Qs ratio of ≥ 1.5:1 or the presence of right ventricular volume overload determined by transthoracic echo (TTE) or clinical symptoms due to the atrial septal defect
- Has a distance of > 5 mm from the margins of the defect(s) to the coronary sinus, arterioventricular (AV) valves and right upper pulmonary vein as measured by echocardiography
- Agrees to participate in the study and comply with the follow-up schedule
- Is willing to freely give (or Legally Authorized Representative is willing to freely give) Informed Consent prior to treatment
- Willing to return for the post-treatment evaluation
Exclusion Criteria:
- Has multiple defects which can't adequately be covered by the device
Has associated congenital cardiac anomalies which require cardiac surgery
a. Has a known sensitivity to contrast media that cannot be controlled adequately with pre-medication.
- Patient is currently participating in another clinical device or drug trial that has not completed its primary endpoint or that will clinically confound the current study endpoints or does not permit subjects to participate in other studies. Typically, subjects that are involved in the long-term surveillance phase of a clinical study are eligible.
- Has ostium primum atrial septal defects
- Has sinus venosus atrial septal defects
- Has partial anomolous pulmonary venous drainage
- Has pulmonary vascular resistance above 7 Woods units or a right-toleft shunt at the atrial level with a peripheral arterial saturation less than 94%
- Has a recent myocardial infarction, unstable angina and decompensated congestive heart failure (CHF)
- Has right and/or left ventricular decompensation with ejection fraction of < 30%
- Has an active bacterial and/or viral infection
- Has any type of serious infection < 1 month prior to the procedure
- Has malignancy where life expectancy is < 2 years
- Has demonstrated intracardiac thrombi on echocardiography
- Weighs < 8 kg
- Has gastritis, gastric ulcer, duodenal ulcer, etc. and other contraindications to aspirin therapy unless other anti-platelet agents can be administered for 6 months
- Has an unstable condition or otherwise thought to be unreliable or incapable of complying with the requirements of the clinical investigational plan (CIP).
- Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Occlutech septal occluder ( Figulla Flex II)
Occlutech septal occluder (Figulla Flex II)
|
transcatheter closure of secundum atrial septal defects in patients
|
Active Comparator: Amplatzer Septal Occluder (ASO)
St. Jude AGA septal occluder (Amplatzer ASO)
|
transcatheter closure of secundum atrial septal defects in patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy: the rate of a successful placement of the device
Time Frame: the day after procedure but no later than 36 hours after the procedure.
|
The primary efficacy endpoint was early efficacy success rate, which was defined as the rate of a successful placement of the device, and successful closure of the defects without major complication, surgical reintervention, device embolization or moderate or large residual shunt the day after procedure but no later than 36 hours after the procedure.
|
the day after procedure but no later than 36 hours after the procedure.
|
Efficacy:The secondary efficacy endpoint is the rate of closure success (residual shunt is smaller than or equal to 2 mm) within 6 months after the procedure, without the need for surgical repair.
Time Frame: within 6 months after the procedure
|
The secondary efficacy endpoint is the rate of closure success (residual shunt is smaller than or equal to 2 mm) within 6 months after the procedure, without the need for surgical repair.
|
within 6 months after the procedure
|
Efficacy:Other efficacy endpoint was the rate of complete closure (no residual shunt) at 6 months after the procedure.
Time Frame: at 6 months after the procedure.
|
Other efficacy endpoint was the rate of complete closure (no residual shunt) at 6 months after the procedure.
|
at 6 months after the procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Major, minor complications rate, all SAEs
Time Frame: 6 and 12 months post procedure
|
Major and complications rate
|
6 and 12 months post procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Occ201201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secundum Atrial Septal Defects
-
Institute of Cardiology, Warsaw, PolandUnknownOstium Secundum Atrial Septal DefectPoland
-
W.L.Gore & AssociatesCompletedSeptal Defect, AtrialUnited States
-
Assiut UniversityWithdrawnASD2(Secundum Atrial Septal Defect)
-
Ayman khairy MohamedCompletedAtrial Septal Defect, Secundum TypeEgypt
-
Abbott Medical DevicesTerminatedAtrial Septal Defect SecundumUnited States
-
W.L.Gore & AssociatesCompleted
-
Henry Ford Health SystemWithdrawn
-
University Hospital, ToulousePhilips HealthcareCompleted
-
Carag AGCompleted
-
Nobles Medical Technologies II IncEnrolling by invitationForamen Ovale, Patent | Septal Defect, Atrial | Septal Defect, HeartUnited States, Italy
Clinical Trials on transcatheter closure of secundum atrial septal defects in patients
-
Skane University HospitalCompletedCongenital Heart Disease
-
Carag AGCompleted
-
University Hospital, ToulouseCompleted
-
China National Center for Cardiovascular DiseasesUnknown
-
Hacettepe UniversityActive, not recruitingNeural Tube Defects | Newborn MorbidityTurkey
-
Tel-Aviv Sourasky Medical CenterRecruitingAtrial FibrillationIsrael
-
University College, LondonSociety for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...Unknown
-
University Hospital, GhentUniversity Hospital, Antwerp; Queen Fabiola Children's University Hospital,...RecruitingPharmacokinetics | Vancomycin | Amoxicillin-clavulanate | Piperacillin-tazobactam | Teicoplanin | Meropenem | Ciprofloxacin | AmikacinBelgium
-
Hospital Israelita Albert EinsteinRecruitingAcute Kidney InjuryBrazil
-
Kansas City Heart Rhythm Research FoundationTexas Cardiac Arrhythmia Research Foundation; Munson Medical CenterRecruitingAtrial Fibrillation | Arrhythmias, CardiacUnited States